Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

This study has been withdrawn prior to enrollment.
Information provided by:
Boehringer Ingelheim Identifier:
First received: July 30, 2008
Last updated: March 26, 2014
Last verified: March 2014
The primary objective of this study is to investigate the effect of 4-week treatment with 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS and placebo on cough and sputum as determined by the CASA-Q (Cough and Sputum Assessment Questionnaire

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Bronchitis, Chronic
Drug: BIBW 2948 BS
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A Phase II, Randomised, Double-blind, Placebo-controlled and Parallel Group Study to Evaluate the Safety and Efficacy of Four Weeks Treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) in Patients With COPD Associated With Chronic Bronchitis.

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The primary endpoint of this study will be change in the Cough and Sputum PRO symptom domain scores from baseline (Visit 2) to the end of the 4 weeks treatment period. [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Cough and Sputum PRO symptom domain scores Cough and Sputum PRO impact domain scores 24 hours sputum wet/dry weight and volume Cough frequency as recorded by electronic recording of thorax movement Interleukin 8 P. Level Cough and Sputum Rating Sc [ Time Frame: 4 weeks ]

Enrollment: 0
Study Start Date: August 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: BIBW 2948 BS
    7.5 mg b.i.d, 15mg q.d, 15mg b.i.d

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.
  2. Male or female patients 40 years of age or older.
  3. Patients must have a diagnosis of COPD defined by a post-bronchodilator FEV1 < 80% of predicted and FEV1 < 70% of FVC (to be obtained 30 minutes after administration of salbutamol HFA). Predicted normal values will be calculated according to ECSC (R94-1408).

    For Height measured in inches


    FEV1 predicted (L) = 4.30 x (height (inches)/39.37) - 0.029 x age (yrs) - 2.49


    FEV1 predicted (L) = 3.95 x [height (inches)/39.37] - 0.025 x age (yrs) - 2.60

    or Height measured in meters


    FEV1 predicted (L) = 4.30 x [height (meters)] - 0.029 x age (yrs) - 2.49


    FEV1 predicted (L) = 3.95 x [height (meters)] - 0.025 x age (yrs) - 2.60

  4. Patients must have a diagnosis of chronic bronchitis symptoms i.e., cough and sputum expectoration on most days for at least three months in each of two consecutive years.
  5. Patients must be a current or ex-smoker with a smoking history of sup or egal to 10 pack years (Patients who have never smoked cigarettes must be excluded).
  6. Patients must be able to perform all specified procedures and able to maintain all necessary records during the study period as required in the protocol.
  7. Patients must be able to inhale medication in a competent manner from the HandiHaler® device for BIBW 2948 BS.
  8. Patients must be able to read and understand the questionnaires in the languages provided (English in the U.S., French in France and German in Germany).

Exclusion Criteria:

  1. Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patients at risk because of participation in the study or may influence either the results of the study or the patient's ability to participate in the study.Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis if the abnormality defines a significant disease as defined in exclusion criteria No. 1.
  2. Patients with an acute or chronic hepatitis or alpha one antitrypsin deficiency or other liver disease.
  3. Patients with an aspartate aminotransferase (AST), alanine aminotransferase (ALT) 1.5 x the upper limit of the normal range will be excluded regardless of the clinical condition. A repeat laboratory evaluation will not be conducted in these patients.
  4. Patients with history of asthma or allergic rhinitis.
  5. Patients with history of post-nasal drip the last 3 months prior visit 1.
  6. Patients with a clinical diagnosis of bronchiectasis.
  7. Patients currently treated with expectorants and/or mucolytics drug.
  8. Patients taking medications with known cough promoting side effects (e.g., angiotensin converting enzyme inhibitors or angiotensin II receptor blockers) that in the opinion of the investigator are causing symptoms of cough.
  9. Patients with any respiratory tract infection or COPD exacerbation in the 30 days prior the visit 1 or during the 1-week period prior to visit 2 (visit 2 will not be postponed and the patient will be discontinued from the study).
  10. Patients who have had any change in their respiratory medications within the last 6 weeks prior the visit 1.
  11. Patients with a history of thoracotomy for other reasons should be evaluated as per Exclusion 1.
  12. Patients with a history of gastroesophageal reflux disease that have changed medication (dose intensification or a change in therapy) to treat this disease within the 6 weeks prior the visit 1.
  13. Patients with a history of cancer, other than treated basal cell carcinoma, within the last five years.
  14. Women of childbearing potential or who have not been post-menopausal for a duration for at least 2 years and have not had a hysterectomy or tubal ligation procedure.
  15. Participation in another trial with an investigational drug within 30 days or 6 half lives (whichever is greater) of the start of the study.
  16. A known hypersensitivity to lactose or any other component of the inhalation capsule or any other components of the inhalation capsule delivery system.
  17. Patients who are currently in a pulmonary rehabilitation program or who have completed a pulmonary rehabilitation program within four weeks prior the visit 1.
  18. Patients with a significant history of significant alcohol or drug abuse.
  19. Patients with previous participation in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00726479

United States, Alabama
1219.4.01001 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
United States, Arizona
1219.4.01007 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
United States, Colorado
1219.4.01006 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado, United States
United States, Connecticut
1219.4.01002 Boehringer Ingelheim Investigational Site
Stamford, Connecticut, United States
United States, Georgia
1219.4.01008 Boehringer Ingelheim Investigational Site
Rincon, Georgia, United States
United States, South Carolina
1219.4.01003 Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
1219.4.01004 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina, United States
1219.4.01005 Boehringer Ingelheim Investigational Site
Union, South Carolina, United States
1219.4.3306A Boehringer Ingelheim Investigational Site
Bethune Cedex, France
1219.4.3306B Boehringer Ingelheim Investigational Site
Bethune Cedex, France
1219.4.3302A Boehringer Ingelheim Investigational Site
Marseille, France
1219.4.3303A Boehringer Ingelheim Investigational Site
Montpellier, France
1219.4.3308A Boehringer Ingelheim Investigational Site
Nice Cedex 1, France
1219.4.3307A Boehringer Ingelheim Investigational Site
Nimes, France
1219.4.3307B Boehringer Ingelheim Investigational Site
Nimes, France
1219.4.3301A Boehringer Ingelheim Investigational Site
Paris Cedex 04, France
1219.4.3305A Boehringer Ingelheim Investigational Site
Toulouse Cedex, France
1219.4.3305B Boehringer Ingelheim Investigational Site
Toulouse Cedex, France
1219.4.49003 Boehringer Ingelheim Investigational Site
Eisenach, Germany
1219.4.49004 Boehringer Ingelheim Investigational Site
Hamburg, Germany
1219.4.49001 Boehringer Ingelheim Investigational Site
Hannover, Germany
1219.4.49006 Boehringer Ingelheim Investigational Site
Mainz, Germany
1219.4.49005 Boehringer Ingelheim Investigational Site
Rodgau-Dudenhofen, Germany
1219.4.49002 Boehringer Ingelheim Investigational Site
Ruedersdorf, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT00726479     History of Changes
Other Study ID Numbers: 1219.4
Study First Received: July 30, 2008
Last Updated: March 26, 2014

Additional relevant MeSH terms:
Lung Diseases
Chronic Disease
Pulmonary Disease, Chronic Obstructive
Acute Disease
Bronchitis, Chronic
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Lung Diseases, Obstructive
Bronchial Diseases
Respiratory Tract Infections processed this record on April 25, 2017